DRMA Dermata Therapeutics, Inc.
Nasdaq · SEC CIK 1853816 · EDGAR
- Bought, last 12 months
- $1,270 1 purchases by 1 insiders
- Sold, last 12 months
- $13.09 1 sales by 1 insiders
- Filings on record
- 89 since 2021-08-17, latest 2026-08-18 17:25
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Bedoya-Toro Munera Maria E | SVP, Regulatory Affairs | $1,270 | — |
| Scott Kathleen D. | Dir | — | $13.09 |
| Van Hoose Kyri K. | SVP, CFO | — | — |
| PROEHL GERALD T | Pres, COB, CEO, Dir, 10% | — | — |
Transactions 38
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2026-08-18 17:25 | 2026-08-16 | DRMA | PROEHL GERALD T | Pres, COB, CEO, Dir, 10% | A - Grant | — | +170.1K | 292.6K | +139% | — |
| D | 2026-08-18 17:21 | 2026-08-16 | DRMA | Van Hoose Kyri K. | SVP, CFO | A - Grant | — | +102.0K | 232.5K | +78% | — |
| 2026-06-16 16:15 | 2026-06-16 | DRMA | Scott Kathleen D. | Dir | S - Sale | $1.19 | -11 | 0 | -100% | -$13.09 | |
| 2026-03-17 | 2026-02-17 | DRMA | Bedoya-Toro Munera Maria E | SVP, Regulatory Affairs | P - Purchase | $1.27 | +1,000 | 1,012 | +8,333% | +$1,270 | |
| D | 2025-12-29 | 2025-12-23 | DRMA | Van Hoose Kyri K. | SVP, CFO | A - Grant | — | +122.5K | 130.4K | +1,556% | — |
| DMI | 2025-12-29 | 2025-12-23 | DRMA | PROEHL GERALD T | Pres, COB, CEO, Dir, 10% | A - Grant | — | +612.7K | 490.3K | New | — |
| D | 2025-01-23 | 2025-01-21 | DRMA | FISHER MARY | Dir | A - Grant | — | +196.9K | 196.9K | +207,212% | — |
| DI | 2025-01-23 | 2025-01-23 | DRMA | HALE DAVID F | Dir | A - Grant | — | +78.7K | 81.0K | +3,553% | — |
| D | 2025-01-23 | 2025-01-21 | DRMA | Van Hoose Kyri K. | SVP, CFO | A - Grant | — | +78.7K | 78.7K | New | — |
| DI | 2025-01-23 | 2025-01-21 | DRMA | PROEHL GERALD T | Pres, CEO, COB, Dir, 10% | A - Grant | — | +787.4K | 799.5K | +6,504% | — |
| 2022-10-07 | 2022-10-06 | DRMA | WIERENGA WENDELL | Dir | A - Grant | $0.00 | +20.7K | 62.4K | +49% | $0 | |
| 2022-10-07 | 2022-10-06 | DRMA | HALE DAVID F | Dir | A - Grant | $0.00 | +30.2K | 75.7K | +66% | $0 | |
| 2022-10-07 | 2022-10-06 | DRMA | Sandler Andrew Seth | Dir | A - Grant | $0.00 | +10.1K | 24.2K | +72% | $0 | |
| 2022-10-07 | 2022-10-06 | DRMA | Bradrick Brittany | Dir | A - Grant | $0.00 | +9,810 | 23.4K | +72% | $0 | |
| 2022-10-07 | 2022-10-06 | DRMA | FISHER MARY | Dir | A - Grant | $0.00 | +9,810 | 23.4K | +72% | $0 | |
| 2022-10-07 | 2022-10-06 | DRMA | Scott Kathleen D. | Dir | A - Grant | $0.00 | +11.4K | 27.1K | +72% | $0 | |
| 2022-07-08 | 2022-07-07 | DRMA | HALE DAVID F | Dir | A - Grant | $0.00 | +26.4K | 45.6K | +138% | $0 | |
| 2022-07-08 | 2022-07-07 | DRMA | Bradrick Brittany | Dir | A - Grant | $0.00 | +8,602 | 13.6K | +171% | $0 | |
| 2022-07-08 | 2022-07-07 | DRMA | Sandler Andrew Seth | Dir | A - Grant | $0.00 | +8,874 | 14.1K | +171% | $0 | |
| 2022-07-08 | 2022-07-07 | DRMA | FISHER MARY | Dir | A - Grant | $0.00 | +8,602 | 13.6K | +171% | $0 | |
| 2022-07-08 | 2022-07-07 | DRMA | WIERENGA WENDELL | Dir | A - Grant | $0.00 | +18.1K | 41.7K | +77% | $0 | |
| 2022-07-08 | 2022-07-07 | DRMA | Scott Kathleen D. | Dir | A - Grant | $0.00 | +9,960 | 15.8K | +171% | $0 | |
| 2022-04-08 | 2022-04-07 | DRMA | WIERENGA WENDELL | Dir | A - Grant | $0.00 | +10.6K | 15.5K | +217% | $0 | |
| 2022-04-08 | 2022-04-07 | DRMA | Sandler Andrew Seth | Dir | A - Grant | $0.00 | +5,190 | 5,190 | New | $0 | |
| 2022-04-08 | 2022-04-07 | DRMA | Scott Kathleen D. | Dir | A - Grant | $0.00 | +5,826 | 5,826 | New | $0 | |
| 2022-04-08 | 2022-04-07 | DRMA | Bradrick Brittany | Dir | A - Grant | $0.00 | +5,031 | 5,031 | New | $0 | |
| 2022-04-08 | 2022-04-07 | DRMA | FISHER MARY | Dir | A - Grant | $0.00 | +5,031 | 5,031 | New | $0 | |
| 2022-04-08 | 2022-04-07 | DRMA | HALE DAVID F | Dir | A - Grant | $0.00 | +15.5K | 19.1K | +423% | $0 | |
| 2021-11-26 | 2021-11-23 | DRMA | PROEHL GERALD T | Pres, CEO, COB, Dir, 10% | P - Purchase | $2.40 | +20.0K | 59.5K | +51% | +$48.0K | |
| DMI | 2021-08-17 | 2021-08-16+ | DRMA | PROEHL GERALD T | Pres, CEO, COB, Dir, 10% | P - Purchase | $4.96 | +152.9K | 152.9K | New | +$758.2K |
| DMI | 2021-08-17 | 2021-08-17 | DRMA | PROEHL GERALD T | Pres, CEO, COB, Dir, 10% | C - Cnv Deriv | — | +2.05M | 1.28M | New | — |
| DI | 2021-08-17 | 2021-08-17 | DRMA | INSLEY THOMAS | CFO | C - Cnv Deriv | — | +4,581 | 14.3K | +47% | — |
| DMI | 2021-08-17 | 2021-08-17 | DRMA | HALE DAVID F | Dir, 10% | C - Cnv Deriv | — | +278.3K | 331.6K | +522% | — |
| DI | 2021-08-17 | 2021-08-17 | DRMA | HALE DAVID F | Dir, 10% | P - Purchase | — | +35.7K | 35.7K | New | — |
| DI | 2021-08-17 | 2021-08-17 | DRMA | Nardo Christopher J. | Senior VP, Development | C - Cnv Deriv | — | +2,439 | 2,439 | New | — |
| DMI | 2021-08-17 | 2021-08-17 | DRMA | Bedoya-Toro Munera Maria E | SVP | C - Cnv Deriv | — | +64.6K | 84.1K | +331% | — |
| D | 2021-08-17 | 2021-08-17 | DRMA | WIERENGA WENDELL | Dir | C - Cnv Deriv | — | +8,163 | 13.0K | +167% | — |
| DM | 2021-08-17 | 2021-08-17 | DRMA | Proehl Investment Ventures LLC | 10% | C - Cnv Deriv | — | +1.99M | 1.57M | New | — |
Purchase Sale Sale after option exercise All abbreviations